Skip to main content
European Commission logo print header

Immune profiling to guide host-directed interventions to cure HBV infections

Descrizione del progetto

Interventi «host-directed» per curare le infezioni da epatite B

L’obiettivo del progetto IP-cure-B, finanziato dall’UE, è quello di sviluppare nuovi concetti curativi per l’epatite B cronica (CHB, Chronic Hepatitis B). Il progetto mira a migliorare le percentuali di guarigione della CHB aumentando l’immunità innata con modulatori immunitari e stimolando risposte immunitarie adattive con un nuovo vaccino terapeutico. I ricercatori identificheranno anche biomarcatori immunitari e virali per la stratificazione dei pazienti e il monitoraggio della risposta al trattamento. L’integrazione di dati biologici e clinici consentirà modelli per la migliore terapia combinata e l’efficacia di nuove terapie curative rispetto allo spettro della malattia e all’eterogeneità del paziente. La piattaforma preclinica sarà valutata in topi umanizzati, combinando strategie immunomodulanti per stimolare l’immunità innata, salvare le cellule T HBV-specifiche esauste e generare risposte adattive anti-HBV. La prova di concetto sarà ottenuta in una sperimentazione clinica di una combinazione di nuovi composti che stimolano l’immunità innata.

Obiettivo

The objective of the project is to develop novel curative concepts for chronic hepatitis B (CHB). Specific aims will be to: 1) improve the rate of functional cure of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine; ii) characterize immune and viral biomarker signatures for patient stratification and treatment response monitoring; iii) integrate biological and clinical data to model the best combination treatment for future trials; iv) model the effectiveness of novel curative therapies with respect to disease spectrum, patient heterogeneity, and constraints of National Health Systems.

The project organization will combine: i) a Proof of Concept clinical trial of a combination of 2 novel compounds stimulating innate immunity; ii) a preclinical immune therapy platform in humanized mice combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses; iii) extensive virologic and immune profiling to identify correlates of cure in patients, iv) the integration of large biological and clinical datasets, v) a cost-effectiveness modelling of new therapeutic interventions, vi) project management, vii) results exploitation and dissemination.

The proposal responds to the work program by: i) including the evaluation of emerging concepts in drug and vaccine development to discover a curative strategy for CHB, a major public health concern for Europe, ii) capitalizing on knowledge of host-pathogen interactions to develop novel immune-based therapies, iii) considering age, gender and viral genetic variations, iv) comprising a clinical trial and a pre-clinical platform for the discovery of novel immune interventions, and selection of relevant biomarkers for validation in established clinical cohorts, v) addressing conditions for effective uptake of the new curative interventions by National Health Systems.

Invito a presentare proposte

H2020-SC1-BHC-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2019-Two-Stage-RTD

Meccanismo di finanziamento

RIA - Research and Innovation action
æ

Coordinatore

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contribution nette de l'UE
€ 4 221 976,69
Indirizzo
Rue de tolbiac 101
75654 Paris
Francia

Mostra sulla mappa

Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Research Organisations
Collegamenti
Altri finanziamenti
€ 1,50

Partecipanti (15)